Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “buy” rating reiterated by Leerink Swann in a research report issued to clients and investors on Wednesday. They currently have a $530.00 price target on the biopharmaceutical company’s stock. Leerink Swann’s price objective points to a potential upside of 30.46% from the company’s previous close.

A number of other research firms also recently commented on REGN. Vetr upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.09 price objective for the company in a report on Tuesday, August 2nd. Canaccord Genuity restated a “hold” rating and set a $450.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Robert W. Baird downgraded Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $505.00 to $448.00 in a report on Friday, August 5th. Cowen and Company restated a “hold” rating and set a $430.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Finally, Roth Capital restated a “buy” rating and set a $520.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $471.78.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.79% during mid-day trading on Wednesday, reaching $403.02. The company’s stock had a trading volume of 162,854 shares. Regeneron Pharmaceuticals has a 52 week low of $329.09 and a 52 week high of $592.59. The firm has a 50-day moving average of $408.70 and a 200-day moving average of $389.50. The firm has a market capitalization of $42.17 billion, a PE ratio of 62.87 and a beta of 1.24.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/regeneron-pharmaceuticals-inc-regn-receives-buy-rating-from-leerink-swann.html

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.17. The business earned $1.21 billion during the quarter, compared to the consensus estimate of $1.24 billion. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The business’s revenue for the quarter was up 21.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.89 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals will post $10.93 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,125 shares of the firm’s stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $425.00, for a total value of $903,125.00. Following the sale, the director now owns 15,125 shares in the company, valued at $6,428,125. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 10.40% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in REGN. FMR LLC raised its position in Regeneron Pharmaceuticals by 9.2% in the second quarter. FMR LLC now owns 9,416,836 shares of the biopharmaceutical company’s stock worth $3,288,642,000 after buying an additional 795,283 shares in the last quarter. Capital World Investors raised its position in Regeneron Pharmaceuticals by 4.4% in the second quarter. Capital World Investors now owns 7,326,626 shares of the biopharmaceutical company’s stock worth $2,558,678,000 after buying an additional 312,008 shares in the last quarter. Wellington Management Group LLP raised its position in Regeneron Pharmaceuticals by 29.8% in the first quarter. Wellington Management Group LLP now owns 6,212,394 shares of the biopharmaceutical company’s stock worth $2,239,195,000 after buying an additional 1,426,801 shares in the last quarter. Vanguard Group Inc. raised its position in Regeneron Pharmaceuticals by 2.0% in the second quarter. Vanguard Group Inc. now owns 4,779,186 shares of the biopharmaceutical company’s stock worth $1,669,035,000 after buying an additional 92,467 shares in the last quarter. Finally, State Street Corp raised its position in Regeneron Pharmaceuticals by 0.5% in the second quarter. State Street Corp now owns 3,093,295 shares of the biopharmaceutical company’s stock worth $1,080,272,000 after buying an additional 15,272 shares in the last quarter. Institutional investors own 68.16% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.